Rx License-Rx

TAB-4377

Use of Repurposed Compounds for the Treatment of Alzheimer’s Disease

Summary: The NIA seeks co-development partners and/or licensees for the further pre-clinical and clinical development of TTI-101, hydroxychloroquine, and Dasatinib to treat Alzheimer’s disease. Description of Technology: There are no effective treatments for Alzheimer’s disease (AD), a progressive brain disease that slowly destroys a person’s memory, cognitive skills and ability to carry out the simplest tasks. AD affects more than 5 million individuals in the United States and ranks as the sixth leading cause of death. The ε4 allele of the apolipoprotein-E (APOE) gene is the strongest genetic risk factor for sporadic or late-onset AD. Heterozygous carriers of the ε4 allele are at three-to-four times greater risk; homozygous carriers are at ten times greater risk. In fact, APOE ε4 carriers accumulate AD neuropathology early in adulthood with earlier age onset of AD compared with ε4 non-carriers. Researchers at the National Institute...

Intelligence Memo

Owner: National Institutes of Health

Core category: Therapeutics

Therapeutic area: Neurology

Indication: Alzheimer's disease

Modality: Biologic

Focus tags: Neurology, Inflammation

Technology tags: Biologic, Small Molecule, Drug Delivery, Biomanufacturing

Mechanism:

Development stage: Preclinical

Patent status: Abandoned; Expired

Availability: Available for license

Plain-English Licensing Breakdown

This is a license opportunity for a therapeutic asset or drug-enabling technology in Neurology. In plain English, the buyer would be licensing science that could become a treatment program, usually after more validation. The current package appears to be preclinical and is associated with National Institutes of Health. The practical first use case is Alzheimer's disease. Public description: Summary: The NIA seeks co-development partners and/or licensees for the further pre-clinical and clinical development of TTI-101, hydroxychloroquine, and Dasatinib to treat Alzheimer’s disease. Description of Technology: There are no.

What is exciting

Already past pure discovery: Preclinical validation gives a buyer something concrete to reproduce, optimize, or package into an IND-enabling plan.

High upside if the mechanism is measurable: Neurology is hard, but biomarkers, retinal surrogates, genetics, or target-engagement readouts can turn a vague CNS story into a fundable experiment.

Delivery can refresh known biology: A better route, depot, local exposure profile, or targeted formulation can create new IP and reduce systemic risk around existing mechanisms.

The License-Rx pivot is the real unlock: The exciting version is not just the university pitch; it is the focused path: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy

Negatives / diligence concerns

Translation still unproven: Animal or lab data may not predict human performance; tox, PK/PD, CMC, and indication selection still need diligence.

Exposure advantage must be real: Delivery stories fail when biodistribution, local tolerability, stability, or payload compatibility does not beat simpler alternatives.

CNS translation is unforgiving: Brain exposure, target engagement, endpoint sensitivity, and placebo/noise risk can make development expensive without a biomarker-first plan.

Risk Flags

  • Human validation and clinical path require diligence.
  • Patent scope and remaining exclusivity need review with counsel.
  • Inventor readiness and licensing terms are not yet verified.

Strategic Pharma Attractiveness

Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Neurology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.

Most logical pharma targets Eli Lilly — Neurodegeneration leadership and biomarker-driven trial infrastructure. Biogen — CNS portfolio gap-filling and translational neurology focus. Roche — CNS diagnostics, biomarkers, and global development scale.

Development Strategy to Increase PoS

First indication: Alzheimer's disease

Study design: Mechanism-first biomarker study before any broad symptomatic endpoint trial.

Key experiments Validate the AI-optimized pivot: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy Run independent replication of the core claim with pre-specified success criteria Generate a partner-facing risk register that separates solved, testable, and unresolved risks

Final Recommendation

Proceed with repositioning: Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Convert CNS risk into a measurable metabolic-rescue or peripheral biomarker strategy

Best next experiment: Run the smallest independent study that validates: Pair the asset with a brain-bioavailable precursor, nasal/local delivery, or exosome/nanoparticle carrier and gate spend on biomarker movement.

Best licensing timing: Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.